scispace - formally typeset
P

Paul J. van der Maas

Researcher at Erasmus University Rotterdam

Publications -  96
Citations -  5655

Paul J. van der Maas is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Health care & Palliative care. The author has an hindex of 37, co-authored 96 publications receiving 5493 citations.

Papers
More filters
Journal ArticleDOI

End-of-life decision-making in six European countries: descriptive study

TL;DR: Investigation in six European countries found medical end-of-life decisions frequently precede dying in all participating countries, with large variations in the extent to which decisions were discussed with patients, relatives, and other caregivers.
Journal ArticleDOI

End-of-Life Practices in the Netherlands under the Euthanasia Act

TL;DR: The Dutch Euthanasia Act was followed by a modest decrease in the rates of euthanasia and physician-assisted suicide, which may have resulted from the increased application of other end-of-life care interventions, such as palliative sedation.
Journal ArticleDOI

Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study

TL;DR: The main determinants of healthcare use in the Netherlands are old age and disabling conditions, particularly mental disability, and this cost will inevitably increase further in an ageing population.
Journal ArticleDOI

Euthanasia and other end-of-life decisions in the Netherlands in 1990, 1995, and 2001

TL;DR: Since 1995, the demand for physician-assisted death has not risen among patients and physicians, who seem to have become somewhat more reluctant in their attitude towards this practice.
Journal ArticleDOI

Health-Related Quality-of-Life Effects of Radical Prostatectomy and Primary Radiotherapy for Screen-Detected or Clinically Diagnosed Localized Prostate Cancer

TL;DR: Prostatectomy and radiotherapy differed in the type of HRQOL impairment, and patients should be made fully aware of the potential benefits and adverse consequences of therapies for early prostate cancer.